Skip to main content
OpenTrials

Clinical trial condition

Waldenstrom Macroglobulinemia

Explore clinical trials studying Waldenstrom Macroglobulinemia. Study availability and eligibility vary by location and protocol.

394 public trials 46 recruiting studies
Refine in advanced search Browse all conditions

Waldenstrom Macroglobulinemia trial results

Completed

APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia

NCT04260217

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • City of Hope Duarte, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Mayo Clinic Jacksonville, Florida, United States
  • Weill Cornell Univ Hospitals New York, United States
View all 14 locations
View Trial Details
Completed

1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation

NCT03133221

Conditions
B-cell Lymphoma, Blood Protein Disorders, Cardiovascular Diseases, +34 more
Locations
  • University of Miami Sylvester Comprehensive Cancer Center Miami, Florida, United States
  • Greenebaum Cancer Center at University of Maryland Medical Center Baltimore, Maryland, United States
  • Medical College of Wisconsin Milwaukee, Wisconsin, United States
View Trial Details
Completed

A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)

NCT04042376

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • The First Hospital of Jilin University Changchun, China
  • First affiliated Hospital of Zhejiang University Hangzhou, China
  • Institute of Hematology and Blood Diseases Hospital Tianjin, China
  • Wuhan Union Hospital Wuhan, China
View Trial Details
Completed

A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)

NCT04062448

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Kameda Medical Center Chiba, Japan
  • National Cancer Center Hospital Chūōku, Japan
  • National Hospital Organization Kumamoto Medical Center Kumamoto, Japan
  • Matsuyama Red Cross Hospital Matsuyama, Japan
View Trial Details
Completed

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

NCT02924402

Conditions
B-Cell Non-Hodgkins Lymphoma, Blood Protein Disorders, Burkitt Lymphoma, +50 more
Locations
  • Moores UC San Diego Cancer Center La Jolla, California, United States
  • Mayo Clinic Jacksonville, Florida, United States
  • Northside Hospital Atlanta, Georgia, United States
  • The University of Chicago Medicine Chicago, Illinois, United States
View all 23 locations
View Trial Details
Completed

Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia

NCT03630042

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Derriford Hospital, Univeristy Hospitals Plymouth NHS Trust Plymouth, Devon, United Kingdom
  • Torbay and South Devon NHS Foundation Trust Torquay, Devon, United Kingdom
  • Royal Bournemouth Hospital, University Hospitals Dorset NHS Foundation Trust Bournemouth, Dorset, United Kingdom
  • St Bartholomew's Hospital, Barts Health NHS Trust London, Greater London, United Kingdom
View Trial Details
Completed

A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)

NCT03053440

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Mayo Clinic Phoenix Phoenix, Arizona, United States
  • City of Hope National Medical Center Duarte, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
View all 58 locations
View Trial Details
Completed

Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)

NCT03332173

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Cancer Hospital Chinese Academy of Medical Sciences Beijing, Beijing Municipality, China
  • Peking Union Medical College Hospital Beijing, Beijing Municipality, China
  • Guangdong Provincial Peoples Hospital Guangzhou, Guangdong, China
  • Henan Cancer Hospital Zhengzhou, Henan, China
View Trial Details
Completed

A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

NCT04274738

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Mass General Hospital Cancer Center Boston, Massachusetts, United States
  • MD Anderson Cancer Center Houston, Texas, United States
View Trial Details

Related conditions